产品说明书
(E)-5-(2-Bromovinyl)-2'-deoxyuridine
 |
同义名 : | 溴夫定 ;Brivudine;Bromovinyldeoxyuridine;BVDU |
| CAS号 : | 69304-47-8 | |
| 货号 : | A320199 | |
| 分子式 : | C11H13BrN2O5 | |
| 纯度 : | 99%+ | |
| 分子量 : | 333.135 | |
| MDL号 : | MFCD00058585 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 190 mg/mL(570.34 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Brivudine is an analog of thymidine, and is incorporated into the viral DNA. It blocks the action of DNA polymerases, thus inhibiting viral replication. It has a stronger antiviral effect against the varicella-zoster virus compared with reference compounds such as aciclovir or penciclovir[3]. It has high, selective activity against varicella zoster virus (VZV), inhibiting VZV replication, possibly through competitive inhibition of viral DNA polymerase, or by acting as an alternative substrate to deoxythymidine triphosphate, causing viral DNA strand breakage. Oral brivudin is generally well tolerated, with a similar tolerability profile to those of oral acyclovir or famciclovir. Nausea was the most commonly reported adverse event[4]. As opposed to the others, brivudine is a non-nephrotoxic drug that should not be administered to immunodepressed patients or to those being treated with 5-fluorouracil[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.00mL 0.60mL 0.30mL |
15.01mL 3.00mL 1.50mL |
30.02mL 6.00mL 3.00mL |
| 参考文献 |
|---|